文献速递神经PETMR

高18F-FDOPA摄取与弥漫性II-III级胶质瘤生长缓慢相关

A high 18F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II-III gliomas.
PubMed 文献 · Br J Radiol · 2018-01-12

本试点研究回顾性纳入20例新诊断弥漫性II-III级胶质瘤患者,评估18F-FDOPA PET的SUVmax比值(>1.8为高摄取)与直径扩展速度(VDE)的关系。结果显示,SUVmax比值>1.8的5例患者VDE均<4 mm/年且均有IDH突变;高摄取与VDE<4 mm/年显著相关(45% vs 0%,P=0.04)。结论提示高18F-FDOPA摄取可能预测肿瘤生长缓慢,其预后意义与IDH突变不同。

要点

  • SUVmax比值>1.8的5例患者均表现为VDE<4 mm/年且存在IDH突变。
  • 高SUVmax比值(>1.8)与VDE<4 mm/年显著相关(45% vs 0%,P=0.04)。
  • 在IDH突变亚组中,高SUVmax比值与VDE<4 mm/年的关联未达统计学显著(45% vs 0%,P=0.10)。

核心结论

  • 在弥漫性II-III级胶质瘤中,高18F-FDOPA摄取可能预测肿瘤生长缓慢,其预后意义与IDH突变不同。

研究设计与样本

  • 回顾性纳入20例新诊断弥漫性II-III级胶质瘤患者(年龄42±10岁,女性10例,IDH突变17例),所有患者均行18F-FDOPA PET并以SUVmax比值定量,同时有系列MRI用于确定VDE。

关键影像表现/征象

  • SUVmax比值>1.8见于5例患者(25%),这5例患者VDE均<4 mm/年(100%)且均有IDH突变(100%)。
  • 高SUVmax比值(>1.8)与VDE<4 mm/年相关:总体人群中高摄取组45% vs 非高摄取组0%(P=0.04)。
  • 在IDH突变亚组中,高SUVmax比值(>1.8)与VDE<4 mm/年相关:高摄取组45% vs 非高摄取组0%(P=0.10)。

诊断标准与关键数值

  • SUVmax比值>1.8定义为高18F-FDOPA摄取,以对侧脑组织为参照计算SUVmax比值。
  • VDE<4 mm/年作为较好预后的标志。

临床应用与阅片要点

  • 在弥漫性II-III级胶质瘤初诊时,18F-FDOPA PET单次成像可能具有预后价值。
  • 高18F-FDOPA摄取(SUVmax比值>1.8)可能提示肿瘤生长缓慢,其预后意义与IDH突变不同。

局限性

  • 本研究的IDH突变亚组中,高SUVmax比值与VDE<4 mm/年的关联未达统计学显著(45% vs 0%,P=0.10)。
  • 本试点研究结论提示高18F-FDOPA摄取可能预测肿瘤生长缓慢,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: In diffuse Grade II-III gliomas, a high 3,4-dihydroxy-6-(18F)-fluoro-L-phenylalanine (18F-FDOPA) positron emission tomography (PET) uptake, with a standardized uptake value (SUVmax)/contralateral brain tissue ratio greater than 1.8, was previously found to be consistently associated with the presence of an isocitrate dehydrogenase (IDH) mutation, whereas this mutation is typically associated with a better prognosis. This pilot study was aimed to ascertain the prognostic value of this high 18F-FDOPA uptake in diffuse Grade II-III gliomas with regard to the velocity of diameter expansion (VDE), which represents an established landmark of better prognosis when below 4 mm per year.

METHODS: 20 patients (42 ± 10 years, 10 female) with newly-diagnosed diffuse Grade II-III gliomas (17 with IDH mutation) were retrospectively included. All had a 18F-FDOPA PET, quantified with SUVmax ratio, along with a serial MRI enabling VDE determination.

RESULTS: SUVmax ratio was above 1.8 in 5 patients (25%) all of whom had a VDE <4 mm/year (100%) and IDH mutation (100%). Moreover, a SUVmax ratio above 1.8 was associated with higher rates of VDE <4 mm/year in the overall population (45 vs 0%, p = 0.04) and also in the subgroup of patients with IDH mutation (45 vs 0%, p = 0.10).

CONCLUSION: This pilot study shows that in diffuse Grade II-III gliomas, a high 18F-FDOPA uptake would be predictive of low tumour growth, with a different prognostic significance than IDH mutation. Advances in knowledge: 18F-FDOPA PET in a single session imaging could have prognostic value in initial diagnosis of diffuse Grade II-III gliomas.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Isal S, Gauchotte G, Rech F, et al. A high 18F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II-III gliomas. Br J Radiol. 2018. PMID: 29271237. doi:10.1259/bjr.20170803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。